Business Summary
The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).
Number of employees: 22
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 52 | 08-12-31 | |
Director of Finance/CFO | - | 19-12-31 | |
Marie Trad
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Ralph Laufer
CTO | Chief Tech/Sci/R&D Officer | - | 18-05-01 |
Marie Deneux
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Lichtlen
BRD | Director/Board Member | 56 | 18-03-31 |
Michel Picot
BRD | Director/Board Member | 72 | - |
Chief Executive Officer | 52 | 08-12-31 | |
Carole Deffez
BRD | Director/Board Member | - | 19-09-25 |
Céline Fantin
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 17,811,140 | 12,983,653 ( 72.90 %) | 13,156 ( 0.0739 %) | 72.90 % |
Company contact information
Lysogene SA
18-20, rue Jacques Dulud Neuilly-sur-Seine
92200, Paris
+33 1 41 43 03 90
http://www.lysogene.comSector
1st Jan change | Capi. | |
---|---|---|
-14.19% | 11.52B | |
+44.16% | 3.27B | |
-19.90% | 2.02B | |
-38.37% | 2.03B | |
-30.21% | 1.44B | |
+16.18% | 1.01B | |
-6.11% | 719M | |
-32.75% | 418M | |
-52.35% | 339M |